The utility of biomarkers for evaluating the genotoxicity of environmental exposures is well documented. Biomarkers of both exposure and effect provide bases for assessing humangenotoxicant interactions and may be indicative of future disease risk. At present, there is little information on the predictive value of these assays for either a population or the individuals tested. This paper describes some aspects of biomarker assays, the possible use of susceptibility measures in biomonitoring protocols, and the need for evaluation of disease relevance. A population study involving epidemiologists, geneticists, toxicologists, statisticians, and physicians is proposed to determine the disease relevance of these biomarkers. Environ Health Perspect 104(Suppl 3): 503-510 (1996) 
Introduction
The number of biomarkers available for evaluating genetic and cancer risks in humans is quite large (1) . Their utility for human monitoring is suggested by a well-known paradigm of environmentally induced cancer ( Figure 1 ) (2), which presents end points for assessing the entire spectrum of human-genotoxicant interactions. These biomarkers begin with exposure and include absorption, metabolism, distribution, critical target interaction (i.e., DNA damage and repair), genetic changes and, finally, disease. Disease is the province of traditional epidemiology; the development of biomarkers has given rise to the field of molecular epidemiology, which uses these biomarkers rather than disease to assess the risks of environmental exposures. However, even though massive efforts have been expended to develop biomarker assays and define their sensitivities, much remains to be done. For example, the central question of disease relevance, widely assumed but never proven, is only beginning to be explored.
The tools of molecular epidemiology may be divided into several categories. There are biomarkers of exposure/dose that detect genotoxic agents at any level of body penetration, including the target DNA. There are biomarkers of susceptibility, which measure interindividual variability in the response to a given level of exposure. Both imply disease relevance, the former at the population level and the latter at the individual level. The disease relevance of these biomarkers is, of course, in the toxicity (carcinogenicity) of the agent of concern, or in unusual susceptibility to the agent, not in the measured biomarker end point per se. An important characteristic for exposure/dose biomarkers is sensitivity, i.e., the ability to detect exposures at levels that exist in real human populations.
Biomarkers of effect, which measure processed genetic damage, i.e., chromosome aberrations or gene mutations, are more complicated. The end points they measure, although defining consequences, are sometimes also used to define exposures, much in the manner discussed above. Because of this, the terminology of exposure/dose and effect biomarkers is somewhat ambiguous, and more mechanistic terms such as reversible (transient) (15, 17, 18) . This reverses the usual assay that used antibodies formed in animals to detect in situ DNA adducts in cells from humans and could permit serological studies in humans to yield information regarding cumulative exposures to carcinogens/mutagens.
Biomarkes of Susceptibility
As used here, biomarkers of susceptibility refer to measurements that reveal interindividual differences in response to genotoxic influences (usually taken to mean genotypic markers). Individuals who are susceptible to various environmental carcinogens/mutagens have greatly heightened genotoxic responses to exposure levels of agents that induce little or no response in nonsusceptible individuals. Figure 3 indicates several kinds of biomarkers of susceptibility.
Genetic screening, another term for evaluating human populations using biomarkers of susceptibility, evolves from the concept that human populations are heterogeneous, i.e., made up of individuals who are genetically and, therefore, inherently susceptible or resistant to various environmental agents. There are many ethical issues associated with the application of biomarkers of susceptibility to genetic screening, including the right to work and insurance and job discrimination.
Metabolic genotypes reveal interindividual differences in ability to activate or detoxify genotoxic agents (19) (20) (21) (22) (23) (24) , which influence internal and biologically effective doses of the reactive forms of deleterious agents that penetrate to in vivo targets. Important genes of this type include those for P450 and other enzymes that convert inactive carcinogens/mutagens to their genotoxic forms, i.e., the class I reactions, and those that conjugate and thereby detoxify these reactive forms, i.e., the class II reactions (22, 23, 25, 26) . Many of these genes are polymorphic in human populations and they potentially explain much of the interindividual differences observed both in genotoxic responses revealed by biomarkers and by disease outcomes (21, 22, 25, 26) . It appears to be the combined genotype at these loci rather than that at a single gene that governs individual susceptibility or resistance.
There are also genetically determined interindividual differences in the ability to repair damage to the DNA (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Individuals with impaired repair capabilities have an increase in irreversible genotoxic damage resulting from the processing of reversible DNA lesions such as adducts. It is now well recognized that persons with such defects have increased susceptibilities to cancer and, indeed, many of the heritable cancer syndromes are due to inherited mutations at such loci (29, (37) (38) (39) (40) (41) (42) . The genes of interest here are those that encode DNA repair enzymes, polymerases, cellcycle, or check-point proteins (32-34, 43,44) . The biomarkers of susceptibility include identification of relevant mutations in the critical genes, identification of mutant proteins, or loss of a critical repair or cellular function. As indicated in Figure  3 , susceptibility due to impaired DNA repair capacity will influence the occurrence of early biological effects in either reporter or disease genes.
One class of genetically determined biomarkers of susceptibility usually not considered part of human biomonitoring includes genetically defined levels of host resistance to the emergence of diseaseusually cancer. As shown in Figure 3 , susceptibility factors will operate after the early biological effects have been induced. At some point, factors such as immunological competence will have to be considered in assessing risk for developing a genotoxic disease such as cancer in the context of given levels of exposure, dose, and early biological effects. For example, a human leukocyte antigen association (HLA-DPB1 glutamate 69) has been shown for a lung disorder related to beryllium exposure (45) .
To include biomarkers of susceptibility in human biomonitoring protocols in any practical way, these biomarkers will have to be developed as reliable and simplified assays and then validated as to their disease relevance. Recent studies in this regard show that variability in biomonitoring results, especially using effect biomarkers, is often attributable to null genotypes for one of the genes of importance in metabolism (34) . Similarly, individuals who are homozygous deficient for DNA repair functions have grossly elevated frequencies of chromosome aberrations or gene mutations (46) (47) (48) (49) . Clearly, it is important to consider interindividual genetically determined susceptibility and resistance factors when making assessments of genetic and cancer risks.
Other kinds of indicators of susceptibility will have to be considered (50 (52) . Future research will have to define the factors and nutrients of relevance to genotoxicity, devise simplified means for their measurements in human populations, and incorporate such measurements into human monitoring protocols. Again, accurate risk assessments require such information.
Finally, the unit of susceptibility or resistance to carcinogens/mutagens may not be the individual per se, but the cell. For genotoxic diseases such as cancer, which are cellular disorders that are usually clonal in origin, the genotoxic event that initiates the disease occurs in a single cell. As noted above, individuals with inherited DNA repair defects have increased frequencies of in vivo chromosome aberrations, somatic mutations, and cancers. These disorders are often referred to as genetic instability syndromes and, at the constitutional level, are functionally homozygous recessive conditions. In affected individuals, all cells in the body are deficient for the necessary stability factor, and the unit of susceptibility is considered to be the individual. One of these disorders, ataxia-telangiectasia, is also suspected of having heterozygous effects in female carriers, causing breast cancer (53, 54) . The ataxia-telangiectasia gene has recently been cloned (30) ; this will allow clear genotyping of heterozygous individuals and the evaluation of possible increased cancer risk.
Undoubtedly, the cancer-prone characteristic of the genetic instability syndromes results from a genetic alteration in a single cell. Because every cell in the body of a homozygous individual is homozygous deficient, the probability that such oncogenic alterations will occur by mutation is very high, i.e., almost one. However, an individual who is a constitutional heterozygote for one of these conditions will almost certainly be a mosaic at the cell level, with a majority population of heterozygous cells and several minority populations of cells that have lost function of the active copy of the relevant gene by somatic mutation or loss of heterozygosity of the single wildtype allele. Actually, calculations reveal that there can be many mutations of the originally wild-type allele, with the extent of the minority cell populations in the individual being determined by the number of these somatic events and, more importantly, the time during fetal development that they occurred. The earlier the inactivating mutation of the intact allele occurs, the larger the resultant deficient clonal cell fraction will be. These cells now homozygous for a genetic instability gene will in effect have acquired a mutator phenotype.
While homozygosity for DNA repair diseases such as ataxia-telangiectasia are very rare, the heterozygotes occur at measurable frequency by Hardy-Weinberg expectations. When the large number of DNA repair, DNA stability, cell cycle, and checkpoint genes are considered, a large proportion of the human population will be constitutionally heterozygous for one or more of these mutator genes. There is also the possibility that dominant negative mutations may occur in these genes, thereby not requiring the individual to be constitutionally heterozygous at those loci. In toto, interindividual differences in susceptibility to cancer could be due to intraindividual interclonal differences in genetic stability. Colon 
Biomarkers ofEffect (Irreversible Genotoxic Responses)
As indicated in Figure 4 , biomarkers of effect can be divided into two classes: those that measure genotoxic events in reporter genomic regions and those that measure genotoxic effects in diseasecritical regions. Traditionally it has been the former that have constituted the effect biomarkers used for human monitoring. More recently, genotoxic events are also being measured in disease-critical genes. These genotoxic events would certainly be expected to have disease relevance, but it must be determined whether they are biomarkers of effect or early indicators of disease.
As shown in Figure 4 , biomarkers of effect include measurements at both the chromosome and the gene levels for both reporter and disease-critical events. Among the chromosome-level reporter events are the traditional nonspecific chromosome aberrations (56, 57) , micronuclei (58) (59) (60) (61) (62) , sister chromatid exchanges (SCE) (56, (63) (64) (65) , and more recently, single-cell electrophoretic determinations of chromosome fragmentation (comet assay) (66, 67 (80) (81) (82) . However, future research must devise methods to assess irreversible genotoxic effects in other cell types. In this regard, our laboratory is devising a method for assessing in vivo hprt mutations that arise in CD34+ myeloid stem cells, the precursors of most nonlymphocytic leukemias, to determine if these cells are a better surrogate for this kind of malignancy. We need assays of in vivo-arising irreversible genotoxic effects in epithelial cells, as well as simple, inexpensive, and reliable molecular assays for specific in vivo mutations.
Population Studies
Future research will improve the current assays used by molecular epidemiology, making them simpler, cheaper, and more reliable, but these are only the tools needed for human monitoring. What will be of paramount importance for this field will be studies of the meaning of human biomonitoring. Specifically, the disease relevance of the biological end points measured, separately or together, must be established in quantitative terms. Disease relevance must be determined at the population level in order to permit and defend public health decisions made at that level, e.g., removal of sources of contamination. If it can be documented that biomarkers have disease Environmental Health Perspectives * Vol 104, Supplement 3 * May 1996 predictability at the individual level, a wide variety of early intervention strategies will be possible. Because disease relevance at the population level usually depends on the toxicity of the agents of concern, it will not be discussed further here. The determination of disease relevance at the individual level is something that must be initiated by those involved in molecular epidemiology. The determination must be expanded beyond the laboratory and encompass field studies of real human populations and the cooperative efforts of epidemiologists, geneticists, toxicologists, and physicians.
Recnt Studies
Reports that at least one of the effect biomarkers, i.e., chromosome aberrations, has disease relevance per se are beginning to appear in the literature. The first concerns a large Nordic cohort study of cancer incidence in individuals who had determinations of chromosome aberrations, micronuclei, or SCE between 1970 and 1988 (83) . Cytogenetic studies were carried out with populations with environmental exposures and with unexposed referents. (Individuals with cancer diagnosed before the study were not, of course, included in the cohort.) Interlaboratory variation was standardized by trichotomizing the data. There was a statistically significant linear trend in that the upper tertile of chromosome aberrations had a greater than 2-fold increase in cancer incidence over the lower tertile; however, there was no positive association of cancer incidence with SCE results (which are biomarkers of exposure). Data with micronuclei were too limited for firm conclusions (83) .
A similar study has recently been reported from Italy in which chromosome aberration results obtained from 17 laboratories, again trichotomized, were correlated with standardized mortality ratios (SMR) for cancer (84 (83, 84) were prospective studies in which cancer incidence or mortality, respectively, were ascertained several decades after the cytogenetic analysis. Although these findings are exciting, it is not practical to base large-scale studies of disease relevance on this design, and multiple biomarkers cannot be assessed in the same general analysis. Rather 
Conclusions
There are a number of biomarkers available for carcinogenicity/mutagenicity monitoring in humans. The assays themselves are becoming more and more sophisticated and are allowing basic questions about carcinogenic and mutagenic mechanisms to be approached in humans. This progress in assays development has occurred in laboratories; however, the availability of biomarkers has resulted in their use in the field for assessing human environmental health risks and has allowed development of the field of molecular epidemiology. As biological rather than disease end points find greater and greater application for assessing human health risks, more attention must be paid to the health relevance and disease predictability of the end points measured. This will require studies of the scope and complexity outlined above and cannot be accomplished in laboratories alone or in the confines of a single discipline. Furthermore, these studies will require a level of national and international cooperation that has not thus far been shown by the genetic toxicology community. Samples and information must be shared, one or more repositories must be created, commitments must be made to continue the research over time, and perhaps wet workshops will have to be conducted. Studies will be group efforts, and the research will be cumulative and develop over time. The scheme suggested above is for an initial disease assessment; others must follow. Also, new and better biomarkers will continually become available, and these also will require validation of this sort. The effort will be great, but so will be the potential benefits.
Traditional epidemiology has been and remains the gold standard for studying disease outcomes in human populations; however, such approaches to human genetic and cancer risks from environmental exposures is impractical because of the infrequency of the disease events, the numbers of individuals therefore required for study, and the long incubation periods of many of the resultant diseases. In any event, the purposes of monitoring the population is defeated because the diseases that are to be prevented must first occur.
The use of biomarkers in molecular epidemiology holds the promise of disease prevention. If successful, monitoring in this way allows one to buy time and initiate measures aimed at true disease prevention. For this to be accomplished, the tools with which human populations are studied must provide information that is interpretable in terms of health risks. Calibrating these tools for this use should become our major research goal.
